CME — CME Group Inc.

The tape is doing the talking: as of 2026-10-21 the stock was up 24.4% over three months, 6.99% over one month and 6.22% in the prior week, and sits near the top of its $218.31–$329.16 52-week range despite a roughly 2% dip on the Q3 print. Record Q3 ADV of 29.4M contracts (up double digits across all six asset classes), international ADV of 9M and record market-data revenue of $243M (+20% YoY) gave buyers a clean story. The sell-side is more muted than the tape: consensus is Hold (14 buy / 18 hold / 5 sell) with a $298.71 average target that is barely above the current price — so the market is paying up on record volumes and volatility, while analysts see the shares as roughly fully valued.

Revenue is lumpy and volatility-driven rather than smoothly compounding: YoY growth ran +6.0% (Q4'24), +10.4% (Q1'25), +10.4% (Q2'25), -2.9% (Q3'25), +8.1% (Q4'25), +14.5% (Q1'26), +0.8% (Q2'26) and +13.0% (Q3'26). That means the headline +13% Q3 2026 figure is flattered by an easy comparison against the -2.9% quarter a year earlier — Q2 2026 grew only 0.8% YoY. TTM revenue is $6.97B, and the consensus next-FY estimate of $7.06B implies just ~1.3% growth, so the forward curve being priced in is close to flat, not accelerating. Operating margin has been range-bound at 61–70% with Q1 the seasonal peak: 60.0% (Q4'23) → 65.3% (Q2'24) → 66.7% (Q2'25) → 69.7% (Q1'26) → 64.9% (Q2'26) → 65.7% (Q3'26), a real but modest ~2.5pt expansion versus Q3 2025's 63.2%. EPS is similarly uneven: +16.1% YoY in Q3'26 and +21.4% in Q1'26, but only +2.5% in Q2'26, and Q4'25's $3.24 was inflated by non-operating items (net income of $1,168.0M exceeded operating income of $1,019.6M). Verdict: stable-to-slowly-improving profitability on a cyclical, record-high volume base — not a structural acceleration.

Fair, not cheap. As of 2026-10-21 the trailing P/E was 24.09x versus a five-year average of 25.22x — a modest discount to its own history — and the forward P/E on the $12.33 next-FY consensus EPS was 23.9x, against an implied forward growth rate of under 2%. PEG of 1.29 is undemanding for a 65%+ operating-margin franchise but not a bargain. On the other hand, price-to-sales at 15.23x sits ~6% above its five-year average of 14.34x, and trailing free cash flow of roughly $4.2B (through Q2 2026) on a $106.2B market cap is only a ~4.0% FCF yield — and since the 4.11% dividend consumes essentially all of earnings, total return depends almost entirely on earnings growth rather than compounding retained capital. Net-net: roughly fairly valued, with the P/E saying slight discount and the P/S and FCF yield saying slight premium.

At $295.31 the stock is within ~1% of the $298.71 consensus target and ~2% below the recent average target of $300.57 (range $270–$337), meaning the market has already paid for the record-volume story. The Q3 beat was small — $3.02 adjusted vs. $2.98 expected — and the stock still slipped on expense/guidance sensitivity, which tells you expectations are high. The key asymmetry: consensus next-FY EPS of $12.33 vs. trailing $12.29 assumes essentially zero EPS growth, so any sustained ADV records or continued 20% data-revenue growth would force upward revisions and justify a higher multiple; conversely, if volatility compresses back toward 2024-25 levels, revenue reverts toward the flat Q2'26 pattern and a 24x multiple on flat earnings has no cushion. This is a stock priced for volatility to stay elevated, not for a turnaround that hasn't shown up.

Overbought and stretched. As of 2026-10-21, RSI(14) stood at 71.95, with the price +7.36% above its 20-day SMA, +7.39% above its 50-day SMA and +5.88% above its 200-day SMA — implying those averages sit clustered around roughly $275–$279, well below the $295.31 last price. The shape is a long flat base followed by a sharp breakout: six-month return of only +3.84% against a three-month return of +24.4%. Entry-timing implication: chasing at RSI 72 after a 7% two-day pop is poor risk/reward; a reset back toward the $275 area where the 20/50/200-day averages converge, or simply an RSI cooling below 60, would offer a far better entry for anyone adding.

• Interest-rate volatility and the path of central-bank policy: CME's flagship rates complex (Treasury and SOFR futures/options) is the single biggest volume driver, and persistent macro uncertainty is currently a tailwind rather than a headwind.
• Equity and index volatility (VIX regime): low-volatility regimes compress equity-derivative volumes and fee revenue, so a return to 2024-style calm would hit the record ADV narrative directly.
• Regulatory scrutiny of central counterparty (CCP) resiliency, Basel capital-adequacy frameworks and crypto-derivatives oversight — higher capital and compliance costs for clearing members, though CME's scale insulates it better than smaller venues.
• Competitive entry in US Treasury futures and crypto derivatives from rival exchange ventures and crypto-native venues, the main long-term threat to CME's rates franchise economics.
• Cloud migration with Google Cloud plus hybrid co-location, which lowers long-term infrastructure overhead but carries near-term transition and expense risk — the exact area the market flagged after the Q3 print.

• Next earnings report on 2027-02-03 (estimated): confirmation of Q4/FY2026 volume records, the expense trajectory behind the post-Q3 guidance sensitivity, and whether the 20%+ growth in market-data revenue sustains.
• Continued record ADV — especially international (9M contracts in Q3 2026) and crypto product suites — plus scaling of the $100B daily capital efficiencies from portfolio margining that keep clients on the platform.
• A macro volatility spike (rate decision surprises, geopolitical shocks, elections) that would drive a step-change in hedging volume and force consensus EPS revisions above the current near-flat $12.33.
• Full commercial rollout of cloud-based client access and hybrid exchange services, which could re-rate the market-data/technology revenue mix over time.

• Volume mean reversion: Q3 2026's +13% revenue growth came against a -2.9% comp, and Q2 2026 grew only +0.8% YoY — the underlying base rate is mid-single-digit, not low-teens.
• Expense and margin pressure — the stock fell ~2% on the Q3 print on guidance/cost sensitivity even though the quarter beat, showing how little room there is for cost slippage at 24x earnings.
• A ~100% payout ratio: the 4.11% yield (which includes CME's variable annual dividend) consumes essentially all of earnings, so a down year in volumes mechanically cuts the dividend and leaves no retained-capital buffer.
• Competitive erosion in Treasury futures and crypto derivatives from new entrants, plus adverse CCP/Basel capital rules that could raise clearing-member costs.
• Valuation and technicals: at roughly the consensus price target with RSI 71.95 and price 7.4% above its 50-day average, near-term upside is limited and the stock is vulnerable to any volatility compression.

CME is a genuinely superb franchise — 82.5% gross, 65.7% operating and 63.1% net margins, debt-to-equity of 0.13, a 0.27 beta and a 4.1% dividend yield — but at $295.31 and ~24x earnings (23.9x forward), with a Hold consensus and a $298.71 average target essentially at the current price, the record-volume story is already in the stock. The business is not cheap enough to buy on quality alone and not cheap at all on a 4% FCF yield with consensus modeling flat forward EPS growth. This is a fairly valued quality compounder with a stretched short-term chart — a name to own on pullbacks toward the high-$270s, not to chase at RSI 72.

I applied a 24.5x multiple — deliberately between the current 24.1x trailing and the five-year average of 25.22x, appropriate for a ~65% operating-margin franchise growing EPS in the mid-single digits with a 4.1% dividend yield — to the $12.33 consensus next-FY EPS, giving $302. Cross-checking with EV/EBITDA: enterprise value of ~$107.4B ($106.2B market cap + $3.43B long-term debt - $2.20B cash) on ~$5.0B of TTM EBITDA is 21.5x, and at that same multiple the equity value lands near $296/share — so $302 sits at the reasonable midpoint of the two methods and implies ~2% upside from the $295.31 price as of 2026-10-21.